Clinical Trial Search

Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…

Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: The Change in Visual Acuity (Number of ETDRS Letters). — 67.8; 71.9; 69.6; 72.9 ETDRS letters

Primary: Percentage Change in Retinal Thickness in the Study Eye at 6 Months Compared to Baseline — -7.89 percentage change in retinal thickness

Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study) — 5.3; 6.6…

Primary: Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline. — 3; 18 participants

Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters

Primary: Change in Central Subfield Thickening From Baseline Through 34 Weeks — -10; -47; -27; -16 microns — p=0.46

Primary: Macular Thickness at 3 Days After Intravitreous Dexamethasone — 438.44; 465.22; 368.22 µm

Primary: BCVA — 0.8; -0.3; -1.8 Letters

Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 44.8; 39.2; 18.1 Percentage of patients…

Primary: Efficacy of Treatment Outcomes by Change in Visual Acuity From Baseline — 69.95; 74 letters

Primary: Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years. — 1; -2; -3 Letter score — p=0.02

Primary: Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline — 33; 36; 39 Eyes

Primary: Visual Acuity — 52 Units on a scale

Primary: Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye — 27.8; 23.6 Percentage of Patients

Primary: Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline — 58.8; 67.6; 8.8 letters

Primary: Mean Change in Best Corrected Visual Acuity — 0.3; 0.33 logMAR units

Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…

Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 33.6; 45.7; 12.3 Percentage of patients…

Primary: Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye — 22.1; 18.7; 13.3 Percentage of Patients

Primary: Average Change From Baseline (CFB) in Best Corrected Visual Acuity (BCVA) in the Study Eye — 1.4; 4.3 letters — p=0.0011

Primary: Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye — 22.3; 18.2; 10.8 Percentage of Patients

Primary: Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost.

Primary: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From…

Primary: Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline…

Primary: Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12 — 6.8; 1.1 letters — p=<0.001

Primary: Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision. — 8.3; 8.5 ETDRS Letters

Primary: Mean Visual Acuity Change — 5.6; 5.8 ETDRS letters